An open-label, single-dose, dose-escalation, and dose-expansion phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAL061 in patients with heterozygous familial hypercholesterolemia (HeFH).
Latest Information Update: 26 Mar 2026
At a glance
- Drugs YOLT 101 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
Most Recent Events
- 26 Mar 2026 New trial record